度洛西汀治疗痛性糖尿病神经病变的疗效观察

在线阅读 下载PDF 导出详情
摘要 中图分类号R971.4文献标识码A文章编号1672-3783(2015)07-0534-01摘要目的观察度洛西汀治疗痛性糖尿病神经病变的临床疗效。方法80例符合痛性糖尿病神经病变诊断标准的患者,随机分为两组,对照组40例,治疗组40例。两组患者均给予降糖综合治疗,血糖控制平稳(空腹血糖<7.0mmol/L,餐后2h血糖<11.1mmol/L)后,治疗组给予度洛西汀60mg/天,对照组给予阿米替林25-75mg/天,共治疗4周。观察两组治疗前后疼痛改善情况、运动神经传导速度(MNCV)、感觉神经传导速度(SNCV)等指标的改变情况。结果治疗4周,两组患者的疼痛有明显改善,治疗组和对照组治疗有效率分别为87.5%和80%,二组比较无显著性差异(P>0.05)。治疗后治疗组神经传导速度的改善较对照组明显,有显著性差异(P<0.05)。结论度洛西汀可明显提高痛性糖尿病神经病变的疗效。
出处 《健康必读》 2015年7期
关键词 度洛西汀 2型糖尿病 痛性糖尿病神经病变ObservationandnursingofduloxetineinthetreatmentofpainfuldiabeticneuropathyAbstractObjectiveToobservetheclinicalefficacyofduloxetineinthetreatmentofpainfuldiabeticneuropathy.Methods80patientswithpainfuldiabeticneuropathydiagnosticcriteria,wererandomlydividedintotwogroups,40casesinthecontrolgroup,thetreatmentgroupof40cases.Twogroupsofpatientsweretreatedwithhypoglycemictherapy,bloodglucosecontrolisstable(FBG<7.0mmol/L,2hBG<11.1mmol/L),Treatmegroupwastreatedwithduloxetinein60mg/d,controlgroupreceivedamitriptyline25-75mg/d,atotalof4woftreatment.Twogroupswereobservedbeforeandaftertreatmentthesymptom improvement,motornerveconductionvelocity(MNCV),sensorynerveconductionvelocity(SNCV)changesintheindex.ResultsFor4weeks,thetwogroupsofpatientswithpainweresignificantlyimproved,thetreatmentgroupandthecontrolgroupthetreatmentefficiencywere87.5% and80%,therewasnosignificantdifferencebetweenthetwogroups(P>0.05).Aftertreatment, nerveconductionvelocityimprovedsignificantlycomparedw
出版日期 2015年07月17日(中国期刊网平台首次上网日期,不代表论文的发表时间)
  • 相关文献

来源期刊

健康必读

相关关键词

度洛西汀 2型糖尿病 痛性糖尿病神经病变ObservationandnursingofduloxetineinthetreatmentofpainfuldiabeticneuropathyAbstractObjectiveToobservetheclinicalefficacyofduloxetineinthetreatmentofpainfuldiabeticneuropathy.Methods80patientswithpainfuldiabeticneuropathydiagnosticcriteria,wererandomlydividedintotwogroups,40casesinthecontrolgroup,thetreatmentgroupof40cases.Twogroupsofpatientsweretreatedwithhypoglycemictherapy,bloodglucosecontrolisstable(FBG<7.0mmol/L,2hBG<11.1mmol/L),Treatmegroupwastreatedwithduloxetinein60mg/d,controlgroupreceivedamitriptyline25-75mg/d,atotalof4woftreatment.Twogroupswereobservedbeforeandaftertreatmentthesymptom improvement,motornerveconductionvelocity(MNCV),sensorynerveconductionvelocity(SNCV)changesintheindex.ResultsFor4weeks,thetwogroupsofpatientswithpainweresignificantlyimproved,thetreatmentgroupandthecontrolgroupthetreatmentefficiencywere87.5% and80%,therewasnosignificantdifferencebetweenthetwogroups(P>0.05).Aftertreatment, nerveconductionvelocityimprovedsignificantlycomparedw